Do Antidepressants in Our Waterways Affect Fish Behavior? The Troubling Truth
"New research reveals how common pharmaceuticals like temazepam and irbesartan are impacting aquatic life, raising questions about water quality and the subtle effects on ecosystems."
For years, scientists have been concerned about the increasing presence of pharmaceuticals in our rivers and streams. These chemicals, which enter the environment through wastewater treatment plants and other sources, can have unintended consequences for wildlife. While it's well-known that certain drugs can affect human behavior, less is understood about how these substances impact animals in their natural habitats.
A recent study published in Aquatic Toxicology sheds light on this issue, focusing on the effects of two common pharmaceuticals—temazepam (an anti-anxiety medication) and irbesartan (a blood pressure medication)—on the behavior of sea trout (Salmo trutta). This research not only highlights the potential risks to aquatic ecosystems but also raises broader questions about water quality and the long-term effects of pharmaceutical pollution.
Researchers from Umeå University and the Swedish University of Agricultural Sciences investigated how exposure to these drugs influences the behavior of sea trout smolts, both in the laboratory and in their natural environment. The results offer surprising insights into how even low concentrations of pharmaceuticals can alter the behavior of fish, with potential implications for their survival and the overall health of aquatic ecosystems.
Pharmaceuticals in Water
The U.S. Environmental Protection Agency's 2026 technical document identifies prescribed medications and some over-the-counter pharmaceuticals for drinking-water benchmarks. If a pharmaceutical exceeds its benchmark, EPA says additional monitoring or research could help protect Americans' drinking water. A 2022 review examined antidepressant consumption trends, occurrence, toxicity, analytical methods, and removal. The U.S. Geological Survey reports that pharmaceuticals enter water through human excretion and flushing, and that many pass through water-treatment plants.
Detection and Treatment Limits
Researchers use analytical approaches including liquid chromatography-tandem mass spectrometry to determine pharmaceuticals in water, sediment, and suspended solids. A 2021 review surveyed methods used to detect antidepressants in urban waters, wastewater-treatment plants, rivers, and oceans. Conventional treatment does not always remove antidepressants completely, and a 2026 review links their detection in surface water and wastewater to high prescription rates, incomplete removal, and persistence. However, one Frontiers study reported that antidepressant concentrations in source and finished water were below that method's detection limit and identified less impact from wastewater-treatment-plant releases on drinking water.
Early Recognition of Pharmaceutical Pollution
A 2021 Springer chapter presents an overview of the origins and toxicity hazards of pharmaceutical pollutants affecting human and aquatic life. It focuses particularly on antibiotic and anti-inflammatory medicines and their by-products. The chapter identifies antibiotics and related by-products as major pharmaceutical pollutants in the context of the high prevalence of infectious diseases. This source provides historical context for recognizing medicines and their residues as environmental contaminants.
Pharmaceuticals in Our Waterways: What Are the Risks to Fish?
The study focused on temazepam and irbesartan because they are frequently detected in surface waters and have known effects on human physiology. Temazepam, a benzodiazepine, is prescribed to treat anxiety and insomnia, while irbesartan is used to manage high blood pressure. Both drugs have conserved targets in teleost fish (bony fish), suggesting they could exert similar therapeutic effects on these animals.
- Laboratory Exposure: Sea trout smolts were exposed to different concentrations of temazepam and irbesartan in controlled laboratory settings to measure tissue bioconcentration (how much of the drug accumulates in their bodies) and behavioral changes.
- Behavioral Assays: The fish underwent behavioral tests, such as the scototaxis assay (measuring anxiety-related behavior) and activity level assessments in specially designed tanks.
- Field Migration Study: Tagged fish were released into a small stream with strategically placed antennas to track their downstream migration speed and behavior in a natural environment.
From Bioaccumulation to Migration
Recent reviews document pharmaceutical effects across marine organisms, including fish such as Argyrosomus regius, Sparus aurata, and Salmo trutta, as well as algae and bivalves. A separate review evaluates bioaccumulation and bioconcentration factors for pharmaceutical compounds in aquatic organisms across different trophic levels. In multi-year laboratory and field experiments involving 730 Atlantic salmon (Salmo salar), researchers found that the anxiolytic pollutant clobazam accumulated in fish brains and influenced river-to-sea migration success. Evidence concerning antidepressants specifically includes research linking internal concentrations of oxazepam with behavioral effects in fish.
Evidence of Ecological Harm
The U.S. Environmental Protection Agency reports that research has found pharmaceuticals entering the environment through flushing and other routes can negatively affect aquatic ecosystems. The agency specifically includes fish and animal populations among those potentially affected. Its summary describes conclusions from scientific studies concerning pharmaceuticals released into the environment. These findings challenge the assumption that disposal practices and environmental dilution eliminate ecological consequences.
Antidepressants Among Emerging Pollutants
A 2025 analysis describes depression as becoming more common and antidepressants as a fast-expanding pharmaceutical category. It argues that antidepressant residues in water should be closely monitored and kept at levels that do not endanger human health, alongside other psychotropic medications. The same analysis reports that these pollutants severely hinder aquatic life. The source therefore frames antidepressants as part of a broader pharmaceutical-pollution problem while emphasizing their particular growth and ecological concern.
Why This Matters: Protecting Our Waterways and Wildlife
This research underscores the importance of considering the subtle, yet significant, effects of pharmaceutical pollution on aquatic ecosystems. By demonstrating that common medications can alter fish behavior, even at low concentrations, the study highlights the need for more comprehensive water quality monitoring and improved wastewater treatment processes.
Pharmaceutical Pollution and Fish
New research reported by The Conversation examined how water containing the antidepressant Prozac affects male guppies. The findings raise concerns about the health of aquatic ecosystems exposed to pharmaceutical pollution. The Cary Institute of Ecosystem Studies describes freshwater organisms as exposed to a mixture that can include antidepressants, amphetamines, birth control, and antihistamines. It reports that research links these compounds to altered organisms and risks to ecosystems, drinking water, and human health, while also describing freshwater pharmaceutical pollution as largely unstudied.